Inside Stocks
Universe/In Vitro & In Vivo Diagnostic Substances/BMRA

Biomerica Inc.

BMRA · US · USD
Watchlist and comparison: planned
Market value4.23 m USD
Industry per SECIn Vitro & In Vivo Diagnostic Substances
Price as of12 Oct 2026
Last financial year2024
Latest filing10-K/A, 28 Sep 2026
Method version2.7.0
Years in the base11
Company quality, four grades from 0 to 5
Balance sheet5
Profitability0
Cash flow0
Growth0
Total points5 of 20
Share valuation, scored separately

No reliable range can be derived for this company. The reason is given below.

The key figures

free to read

All values from audited annual reports filed with the US regulator SEC. No value is estimated, none smoothed.

GradePointsBasis
Balance sheet5/5not reported · Current ratio 2.8
How this grade is built
Net debt to operating incomenot reported5/51: ≤ 5.0×2: ≤ 4.0×3: ≤ 3.0×4: ≤ 2.0×5: ≤ 1.0×
Current ratio2.85/51: ≥ 0.82: ≥ 1.03: ≥ 1.34: ≥ 1.85: ≥ 2.5
Mean 5 + 5 / 2 = 5.00, rounded 5
Profitability0/5Operating margin -96.7% · Return on equity -121.1%
How this grade is built
Operating margin-96.7%0/51: ≥ 0.0%2: ≥ 5.0%3: ≥ 12.0%4: ≥ 20.0%5: ≥ 30.0%Next step: at least 0.0% for grade 1
Return on equity-121.1%0/51: ≥ 0.0%2: ≥ 5.0%3: ≥ 10.0%4: ≥ 18.0%5: ≥ 25.0%Next step: at least 0.0% for grade 1
Mean 0 + 0 / 2 = 0.00, rounded 0
Cash flow0/5Free cash flow to revenue -72.3% · Profit covered by cash flow not reported · Free cash flow positive 0 of 5 years
How this grade is built
Free cash flow to revenue-72.3%0/51: ≥ 0.0%2: ≥ 5.0%3: ≥ 10.0%4: ≥ 18.0%5: ≥ 25.0%Next step: at least 0.0% for grade 1
Profit covered by cash flownot reported—1: ≥ 0.4×2: ≥ 0.6×3: ≥ 0.8×4: ≥ 1.0×5: ≥ 1.2×
Free cash flow positive0 of 5 years0/51: 1 of 52: 2 of 53: 3 of 54: 4 of 55: 5 of 5Next step: at least 1/5 for grade 1
Mean 0 + 0 / 2 = 0.00, rounded 0
Growth0/5Revenue growth per year -4.5% · Operating income per year not reported
How this grade is built
Revenue growth per year-4.5%0/51: ≥ 0.0%2: ≥ 3.0%3: ≥ 8.0%4: ≥ 15.0%5: ≥ 25.0%Next step: at least 0.0% for grade 1
Operating income per yearnot reported—1: ≥ 0.0%2: ≥ 3.0%3: ≥ 8.0%4: ≥ 15.0%5: ≥ 25.0%
Mean 0 / 1 = 0.00, rounded 0

Each grade is the rounded mean of two or three key figures, each placed on a five-step scale. Open the derivation under a grade to see, for every figure, the measured value, the step it reached and what the next step would have required.

The valuation range

free to read

No range is reported for this company. Not enough history.

Within the sector

free to read

Rank 11 of 13 in the industry. Median of total points in this industry: 9.0 of 20, across 13 graded companies. The grades are absolute and are not normalised to the sector: in a weak industry a weak grade stays weak.

one place above
Alpha Teknova, Inc.
TKNO
7/20
one place below
Celldex Therapeutics, Inc.
CLDX
5/20

The neighbours follow from the ranking alone, not from a judgement. More total points does not mean a company is the better investment, only that more quality rules are met. It says nothing about the price.

The series of figures

free to read

Every figure comes from the annual report of that year and has not been revised afterwards. Amounts in USD.

Swipe sideways for all columns.

YearRevenueOperating profitFree cash flowEarnings per shareSharesNet debt
20144.96 m-670.60 k-415.98 k-0.281.08 m-1.09 m
20155.14 m-826.95 k-300.34 k-1.401.09 m-1.89 m
20165.79 m-954.63 k-818.94 k-0.771.19 m-1.23 m
20175.56 m-1.48 m-1.30 m-1.191.22 m-1.20 m
20185.20 m-2.41 m-2.35 m-1.821.32 m-686.78 k
20196.69 m-2.74 m-4.33 m-1.821.45 m-8.64 m
20207.20 m-7.50 m-5.39 m-4.341.70 m-4.20 m
202118.87 m-4.53 m-536.00 k-2.521.81 m-5.92 m
20225.34 m-7.22 m-5.54 m-3.502.02 m-9.72 m
20235.42 m-6.37 m-5.41 m-2.842.10 m-4.17 m
20245.31 m-5.14 m-3.84 m-2.162.30 m-2.40 m

How durable the advantage is

free to read

0 of 10 points, measured over 10 years (2015 to 2024). Classification: no trace.

FeaturePointsBasis
Return on capital, level0/3The company earns on average -42.9% of its assets per year as operating profit, measured over 10 years. Comparable companies are around 10%.
Return on capital, consistency0/30 of 10 years above 10%. Consistency is the real evidence, because anyone has one good year.
Pricing power0/2Gross margin averaging 20%, trending -20.3 percentage points from the first third to the last. A margin that holds for a decade is pricing power. One that melts away is competition.
Stability in a downturn0/2Operating margin averaging -44%. Tested in 2020 and 2022: 2020 -104%, 2022 -135%. Holding counts from two thirds of the company's own average.

What is measured is the trace of a moat: a durably high return on capital and margins that survive a downturn. The causes (switching costs, network effects, brand, licences, economies of scale) appear in no filing and are not claimed here.

Next figures

Expected on 13 Oct 2026 (estimated from the rhythm of earlier filings, ± 5 days). Grades can change after a report; the page is then rebuilt.

Required disclosures for this analysis

Produced byFlorian Maier
Completed on14.10.2026 03:58
Price as of12 Oct 2026
Latest filing10-K/A, 28 Sep 2026
Method version2.7.0
Time horizonThe grades describe a state that can change with every annual report, so roughly quarterly. The historical analysis is computed over 36 months.
Own positionNot disclosed individually, see the risk notice.
Earlier analysesThe list of all analyses of this company from the past twelve months will appear once twelve months of analyses exist. This run is the start of the series.

This is not investment advice. Limits of the method, assumptions and conflicts of interest: risk notice.